Gastroenterology Clinics of North America, Journal Year: 2024, Volume and Issue: 54(2), P. 333 - 350
Published: Dec. 4, 2024
Language: Английский
Inflammatory Bowel Diseases, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 14, 2025
Abstract Background Fecal microbiota transplantation (FMT) is emerging as a potential treatment modality for individuals living with inflammatory bowel disease (IBD). Despite its promise, the effectiveness of FMT treating IBD, particularly ulcerative colitis (UC), still requires thorough clinical investigation. Notwithstanding differences in methodologies, current studies demonstrate inducing remission UC patients. Therefore, standardized and robust randomized trials (RCTs) are needed to further support efficacy managing UC. The aim second Rome Consensus Conference was address gaps uncertainties identified previous research regarding offer framework future applied Methods Global experts field mucosal immunology, microbiology (N = 48) gathered need group focused on key issues, such stool donation, donor selection, characterization fecal biomass, administration routes, well process induction, maintenance, endpoint readouts. Results Conclusions consensus achieved during this conference established standardization methods protocols enhance quality research, eventual implementation ultimate goal improving patient outcomes.
Language: Английский
Citations
1
Brain Behavior and Immunity, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Citations
5
Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)
Published: Jan. 2, 2025
The development of fecal microbiota transplantation and defined live biotherapeutic products for the treatment human disease has been an empirically driven process yielding a notable success approved drugs recurrent
Language: Английский
Citations
0
Gut Microbes Reports, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 20
Published: Jan. 15, 2025
Autoimmune thyroid diseases (AITDs) are the most common organ-specific autoimmune disorders characterized by dysfunction and immune system deficiencies. In recent decades, role of microbiome in has gained increasing attention, with emerging research linking gut alterations to development AITDs. This review summarizes current knowledge on relationship between AITDs microbiome. Additionally, it emphasizes oral AITDs, an area often overlooked research. Beyond microbiome, virome mycobiome have been recognized as critical but underexplored components human potentially contributing dysregulation pathogenesis The also explores modulating for managing including diet adjustment, potential use probiotics, postbiotics, symbiotics, even fecal microbiota transplantation (FMT) restore a balanced that may positively influence and, extension, course thoroughly intricate gut, microbiomes, paving way precision medicine applications Examining microbiota-thyroid interactions highlights targeted, personalized treatments novel therapeutic therapies, guiding future strategies more effective precisely tailored AITD management approaches.
Language: Английский
Citations
0
Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)
Published: March 10, 2025
Microbiota transplant therapy is an emerging for inflammatory bowel disease, but factors influencing its efficacy and mechanism remain poorly understood. In this narrative review, we outline key elements affecting therapeutic outcomes, including donor (such as age patient relationship), recipient factors, control selection, impacting engraftment correlation with clinical response. We also examine potential mechanisms through disease trials, focusing on the interplay between microbiota, host, immune system. Finally, briefly explore future directions microbiota promising treatments.
Language: Английский
Citations
0
Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16
Published: March 25, 2025
Fecal microbiota transplantation (FMT) represents a therapeutic approach that directly regulates the gut of recipients, normalizes its composition and reaping rewards. Currently, in addition to general application treating Clostridium difficile ( C. ) infection (CDI), FMT treatment has also been extended fields other gastrointestinal diseases, infections, gut-liver or gut-brain axis disorders, metabolic diseases cancer, etc. Prior FMT, rigorous donor screening is essential reduce occurrence adverse events. In addition, it imperative evaluate whether recipient can safely effectively undergo treatment. However, efficacy influenced by complex interactions between recipient, degree engraftment not necessarily positively related with success rate FMT. Furthermore, an increasing number novel factors affecting outcomes are being identified recent clinical trials animal experiments, broadening our understanding This article provides comprehensive review scenarios influencing safety from aspects both donors summarizes how these emerging regulatory be combined predict patients undergoing
Language: Английский
Citations
0
Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)
Published: April 7, 2025
Inflammatory Bowel Disease (IBD) is a spectrum of chronic inflammatory diseases the intestine that includes subtypes ulcerative colitis (UC) and Crohn's (CD) currently has no cure. While IBD results from complex interplay between genetic, environmental, immunological factors, sequencing advances over last 10-15 years revealed signature changes in gut microbiota contribute to pathogenesis IBD. These findings highlight as disease target for microbiome-based therapies, with potential treat underlying microbial provide adjuvant therapy emerging advanced therapies Building on success fecal transplantation (FMT) Clostridioides difficile infection, targeting have emerged promising approaches treating IBD; however, unique aspects need more precision approach microbiome therapeutics leverage recipient donor selection, diet xenobiotics, strain-specific interactions enhance efficacy safety therapy. This review focuses both pre-clinical clinical studies support premise aims framework development optimize outcomes patients
Language: Английский
Citations
0
Pediatric Research, Journal Year: 2025, Volume and Issue: unknown
Published: May 7, 2025
Language: Английский
Citations
0
Journal of Crohn s and Colitis, Journal Year: 2024, Volume and Issue: 19(2)
Published: Sept. 3, 2024
Fecal microbiota transplantation (FMT) is an experimental treatment for ulcerative colitis (UC). We aimed to study microbial families associated with FMT success. analyzed stools from 24 UC patients treated 4 FMTs weekly after randomization pretreatment during 3 weeks budesonide (n = 12) or placebo 12). Stool samples were collected 9 times pre-, during, and post-FMT. Clinical endoscopic response was assessed 14 initiation of the using full Mayo score. Early withdrawal due worsening symptoms classified as non-response. Nine (38%) reached remission at week 14, 15 had a partial non-response before 14. With Dirichlet multinomial mixture model, we identified 5 distinct clusters based on composition 180 longitudinally patient 27 donor samples. A Prevotellaceae-dominant cluster poor treatment. Conversely, Ruminococcaceae Lachnospiraceae successful clinical response. These associations already visible start subgroup retained in repeated measures analyses family-specific abundance over time. Responders also characterized by significantly lower Simpson dominance compared non-responders. The success appears be specific gut families, such control Prevotellaceae. Monitoring dynamics these could potentially used inform early FMT. registered Netherlands Trial Register, reference number NL9858.
Language: Английский
Citations
3
Microorganisms, Journal Year: 2024, Volume and Issue: 12(11), P. 2256 - 2256
Published: Nov. 7, 2024
This review explores the complex relationship between gut dysbiosis and hematological malignancies, focusing on graft-versus-host disease (GvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We discuss how alterations microbial diversity composition can influence development, progression, treatment outcomes blood cancers. The mechanisms by which microbiota impacts these conditions are examined, including modulation of immune responses, production metabolites, effects intestinal barrier function. Recent advances microbiome-based therapies for treating preventing GvHD highlighted, with emphasis full ecosystem standardized donor-derived products. Overall, this underscores growing importance microbiome research hematology–oncology its potential to complement existing treatments improve thousands patients worldwide.
Language: Английский
Citations
2